Wyeth Moves To Broaden Prevnar: Prepares Offer For Crucell
This article was originally published in The Pink Sheet Daily
Executive Summary
Crucell would fit Wyeth’s ongoing effort to extend geographic base for vaccines and provide new candidates and technologies to provide depth to the company’s vaccine R&D effort.